Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Belite Bio
(NASDAQ:BLTE)
Intraday
$32.91
-4.36
[-11.70%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$32.91
-4.36
[-11.70%]
Last update: 9:20AM
Get Real Time Here
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Belite Bio Stock (NASDAQ:BLTE)
Belite Bio Stock (NASDAQ: BLTE)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, March 22, 2024
HC Wainwright & Co. Maintains Buy on Belite Bio, Maintains $59 Price Target
Benzinga Newsdesk
-
Mar 22, 2024, 11:13AM
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
Benzinga Newsdesk
-
Mar 22, 2024, 8:01AM
Wednesday, March 13, 2024
HC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $59 Price Target
Benzinga Newsdesk
-
Mar 13, 2024, 7:00AM
Tuesday, March 12, 2024
Belite Bio Q4 EPS $(0.25) Beats $(0.30) Estimate
Benzinga Newsdesk
-
Mar 12, 2024, 1:59AM
Wednesday, December 27, 2023
HC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $59 Price Target
Benzinga Newsdesk
-
Dec 27, 2023, 11:45AM
Thursday, December 14, 2023
Expert Ratings for Belite Bio
Benzinga Insights
-
Dec 14, 2023, 12:00PM
Maxim Group Initiates Coverage On Belite Bio with Buy Rating, Announces Price Target of $60
Benzinga Newsdesk
-
Dec 14, 2023, 9:11AM
Sunday, December 10, 2023
Belite Bio Received Approval To Initiate Tinlarebant Phase 3 Clinical Trial For GA in Switzerland
Charles Gross
-
Dec 10, 2023, 12:45PM
Wednesday, November 15, 2023
HC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $59 Price Target
Benzinga Newsdesk
-
Nov 15, 2023, 7:05AM
Tuesday, November 14, 2023
Earnings Scheduled For November 14, 2023
Benzinga Insights
-
Nov 14, 2023, 8:23AM
Monday, November 13, 2023
Belite Bio Q3 EPS $(0.40) Down From $(0.10) YoY
Benzinga Newsdesk
-
Nov 13, 2023, 9:06PM
Tuesday, November 07, 2023
Benchmark Reiterates Buy on Belite Bio, Maintains $57 Price Target
Benzinga Newsdesk
-
Nov 7, 2023, 12:18PM
Monday, November 06, 2023
HC Wainwright & Co. Maintains Buy on Belite Bio, Raises Price Target to $59
Benzinga Newsdesk
-
Nov 6, 2023, 11:46AM
Belite Bio Presented Final Data From A 24-month, Phase 2 Study Of Tinlarebant In In Childhood-onset Stargardt Disease At The American Association Of Ophthalmology Annual Meeting
Benzinga Newsdesk
-
Nov 6, 2023, 8:05AM
Tuesday, October 17, 2023
Belite Bio Announces NMPA Submission For Tinlarebant Phase 3 GA Clinical Trial In China
Benzinga Newsdesk
-
Oct 17, 2023, 4:24PM
Wednesday, August 30, 2023
Belite Bio shares are trading lower. Not seeing any news to justify the price action.
Benzinga Newsdesk
-
Aug 30, 2023, 3:51PM
Monday, August 14, 2023
Why 22nd Century Group Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin
-
Aug 14, 2023, 12:49PM
Thursday, August 10, 2023
Expert Ratings for Belite Bio
Benzinga Insights
-
Aug 10, 2023, 3:00PM
HC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $55 Price Target
Benzinga Newsdesk
-
Aug 10, 2023, 7:17AM
Wednesday, August 09, 2023
Earnings Scheduled For August 9, 2023
Benzinga Insights
-
Aug 9, 2023, 4:54AM
Belite Bio Q2 EPS $(0.26) Down From $(0.12) YoY
Benzinga Newsdesk
-
Aug 9, 2023, 2:05AM
Friday, August 04, 2023
Belite Bio Receives Approval To Initiate Tinlarebant Phase 3 Clinical Trial For Ga In Australia
Benzinga Newsdesk
-
Aug 4, 2023, 8:08AM
Friday, July 28, 2023
Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2023
Benzinga Insights
-
Jul 28, 2023, 11:00AM
Cantor Fitzgerald Initiates Coverage On Belite Bio with Overweight Rating, Announces Price Target of $43
Benzinga Newsdesk
-
Jul 28, 2023, 7:45AM
Thursday, July 27, 2023
Belite Bio Doses First Subject In Pivotal Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant For Geographic Atrophy
Happy Mohamed
-
Jul 27, 2023, 5:19PM
Wednesday, July 26, 2023
Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2023
Benzinga Insights
-
Jul 26, 2023, 11:00AM
SVB Leerink Initiates Coverage On Belite Bio with Outperform Rating, Announces Price Target of $25
Benzinga Newsdesk
-
Jul 26, 2023, 7:11AM
Tuesday, July 25, 2023
The Latest Analyst Ratings for Belite Bio
Benzinga Insights
-
Jul 25, 2023, 9:00AM
Benchmark Reiterates Buy on Belite Bio, Maintains $57 Price Target
Benzinga Newsdesk
-
Jul 25, 2023, 8:37AM
HC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $55 Price Target
Benzinga Newsdesk
-
Jul 25, 2023, 6:19AM
Monday, July 24, 2023
Belite Bio Completes Enrollment In Its Pivotal Tinlarebant Global Phase 3 DRAGON Trial For Patients With Stargardt Disease
Benzinga Newsdesk
-
Jul 24, 2023, 6:06AM
Tuesday, June 27, 2023
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
-
Jun 27, 2023, 1:37PM
Monday, June 26, 2023
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights
-
Jun 26, 2023, 1:37PM
Why Carnival Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin
-
Jun 26, 2023, 12:31PM
Wolfspeed, Genesco, PacWest Bancorp And Other Big Stocks Moving Higher On Monday
Lisa Levin
-
Jun 26, 2023, 10:13AM
Tuesday, June 20, 2023
Analyst Expectations for Belite Bio's Future
Benzinga Insights
-
Jun 20, 2023, 1:02PM
Benchmark Reiterates Buy on Belite Bio, Maintains $57 Price Target
Benzinga Newsdesk
-
Jun 20, 2023, 8:12AM
Friday, June 16, 2023
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
-
Jun 16, 2023, 1:08PM
Friday, June 09, 2023
Top 5 Health Care Stocks That Are Set To Fly In Q2
Lisa Levin
-
Jun 9, 2023, 8:40AM
Monday, June 05, 2023
HC Wainwright & Co. Reiterates Buy on Belite Bio, Lowers Price Target to $55
Benzinga Newsdesk
-
Jun 5, 2023, 10:14AM
Wednesday, May 31, 2023
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights
-
May 31, 2023, 1:31PM
Why Capri Holdings Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Lisa Levin
-
May 31, 2023, 1:01PM
Nasdaq Down 100 Points; Advance Auto Parts Earnings Miss Views
Lisa Levin
-
May 31, 2023, 12:06PM
Dow Tumbles Over 200 Points; Chicago PMI Drops In May
Lisa Levin
-
May 31, 2023, 10:28AM
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
-
May 31, 2023, 9:06AM
Why LL Flooring Shares Are Trading Higher By 19%; Here Are 20 Stocks Moving Premarket
Lisa Levin
-
May 31, 2023, 8:39AM
Belite Bio shares are trading lower after the company announced pricing of a $30 million underwritten public offering of ADSs and warrants.
Benzinga Newsdesk
-
May 31, 2023, 8:12AM
HP, Ambarella, Sportsmans Warehouse And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Lisa Levin
-
May 31, 2023, 6:31AM
Tuesday, May 30, 2023
Belite Bio Announces Proposed Underwritten Public Offering Of ADSs, Warrants; Size, Price Not Disclosed
Benzinga Newsdesk
-
May 30, 2023, 4:02PM
Monday, May 22, 2023
Belite Bio Inc Files For Mixed Shelf Of Up To $300M
Benzinga Newsdesk
-
May 22, 2023, 5:09PM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch